Literature DB >> 25098308

18F-fluoro-2-deoxy-D-glucose retention index as a prognostic parameter in patients with pancreatic cancer.

Yun Xi1, Rui Guo, Jiajia Hu, Min Zhang, Xiangming Zhang, Biao Li.   

Abstract

OBJECTIVES: The objective of this study was to determine the most effective way to use dual-phase F-fluoro-2-deoxy-D-glucose (F-FDG) PET/computed tomography (CT) semiquantitative indices to predict prognosis in patients with pancreatic cancer and to guide treatment. STUDY
DESIGN: Prognostic parameters were retrospectively analyzed in 40 patients with histologically proven pancreatic cancer who received F-FDG PET/CT at Ruijin Hospital. Maximum standardized uptake values (SUVs) were determined at 1 h (SUV1) and 2 h (SUV2) after F-FDG injection. The retention index (RI) was defined as the percentage change between SUV1 and SUV2.
RESULTS: RI less than 17% was explored as having a significant independent correlation with prolonged patient survival (P<0.05). Patients with tumor resection and RI less than 17% survived significantly longer than those with or without tumor resection and RI of 17% or higher (P<0.05). Neither SUV1, nor SUV2 showed any prognostic significance, but they did show a positive correlation with tumor diameter (P1<0.01; P2<0.05); RI had a strong positive correlation with tumor, node, and metastasis stage (P<0.01). Two factors were found to be associated with RI, including pancreatitis (P<0.05) and diabetes (P<0.01).
CONCLUSION: RI served as the most accurate parameter to predict disease prognosis in pancreatic cancer and to identify patients who could benefit from surgery. However, pancreatitis and diabetes had a potential impact on RI, reflecting the influence of tumor pathophysiological changes on the metabolism of glucose in pancreatic tumor cells. Therefore, further comprehensive analyses are required.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25098308     DOI: 10.1097/MNM.0000000000000178

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  5 in total

Review 1.  Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals.

Authors:  Yu-Ping Xu; Min Yang
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

2.  Preoperative 2-[18F]FDG PET-CT aids in the prognostic stratification for patients with primary ampullary carcinoma.

Authors:  Pei-Ju Chuang; Hsiu-Po Wang; Yu-Jen Lin; Chieh-Chang Chen; Yu-Wen Tien; Min-Shu Hsieh; Shih-Hung Yang; Ruoh-Fang Yen; Chi-Lun Ko; Yen-Wen Wu; Mei-Fang Cheng
Journal:  Eur Radiol       Date:  2021-04-17       Impact factor: 5.315

3.  The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase (18)F-FDG PET/CT.

Authors:  Hansol Moon; Woo Chul Noh; Hyun-Ah Kim; Eun-Kyu Kim; Ko Woon Park; Seung Sook Lee; Joon Ho Choi; Kyung Woo Han; Byung Hyun Byun; Ilhan Lim; Byung Il Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Nucl Med Mol Imaging       Date:  2016-04-11

Review 4.  The clinical application of 18F-FDG PET/CT in pancreatic cancer: a narrative review.

Authors:  Yongzhu Pu; Chun Wang; Sheng Zhao; Ran Xie; Lei Zhao; Kun Li; Conghui Yang; Rui Zhang; Yadong Tian; Lixian Tan; Jindan Li; Shujuan Li; Long Chen; Hua Sun
Journal:  Transl Cancer Res       Date:  2021-07       Impact factor: 1.241

5.  Prognosis prediction of pancreatic cancer after curative intent surgery using imaging parameters derived from F-18 fluorodeoxyglucose positron emission tomography/computed tomography.

Authors:  Min Young Yoo; Yoo-Seok Yoon; Min Seok Suh; Jai Young Cho; Ho-Seong Han; Won Woo Lee
Journal:  Medicine (Baltimore)       Date:  2020-08-28       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.